Halozyme Therapeutics (HALO) Invested Capital (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Invested Capital data on file, last reported at $955.3 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $955.3 million, down 51.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $955.3 million (down 51.99% YoY), and the FY2025 annual result was $783.6 million, down 58.09% from the prior year.
• Invested Capital improved to $955.3 million in Q1 2026 per HALO's latest filing, from $783.6 million in the prior quarter.
• Over five years, Invested Capital peaked at $2.0 billion in Q3 2025 and troughed at $783.6 million in Q4 2025.
• A 5-year average of $1.6 billion and a median of $1.7 billion in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital jumped 70.28% in 2022, then tumbled 58.09% in 2025.
• A 5-year view of Invested Capital shows it stood at $1.7 billion in 2022, then retreated by 5.54% to $1.6 billion in 2023, then climbed by 18.1% to $1.9 billion in 2024, then plunged by 58.09% to $783.6 million in 2025, then rose by 21.91% to $955.3 million in 2026.
• Business Quant data shows HALO's Invested Capital at $955.3 million in Q1 2026, $783.6 million in Q4 2025, and $2.0 billion in Q3 2025.